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Abstract
MicroRNA (miRNA) dysregulation frequently occurs in cancer. Analysis of whole blood miRNA in
tumor models has not been widely reported, but could potentially lead to novel assays for early
detection and monitoring of cancer. To determine whether miRNAs associated with malignancy
could be detected in the peripheral blood, we used real-time reverse transcriptase-PCR to
determine miRNA profiles in whole blood obtained from transgenic mice with c-MYC-induced
lymphoma, hepatocellular carcinoma and osteosarcoma. The PCR-based assays used in our studies
require only 10 nanograms of total RNA, allowing serial mini-profiles (20 – 30 miRNAs) to be
carried out on individual animals over time. Blood miRNAs were measured from mice at different
stages of MYC-induced lymphomagenesis and regression. Unsupervised hierarchical clustering of
the data identified specific miRNA expression profiles that correlated with tumor type and stage.
The miRNAs found to be altered in the blood of mice with tumors frequently reverted to normal
levels upon tumor regression. Our results suggest that specific changes in blood miRNA can be
detected during tumorigenesis and tumor regression.
Findings
Distinct miRNA profiles have been described for many
cancers including hematologic and solid malignancies [1-
12]. Many reports have shown that patterns of miRNA
expression differ between normal and cancerous tissues
[1-10,12-20]. Gene expression profiling of traditional
mRNA targets in whole blood or fractionated leukocytes
has also shown correlations with many types of both neo-
plastic and non-neoplastic human disease, for example
renal cancer and Crohn's disease [21-30]. To investigate
whether miRNA patterns in blood correlated with tumor-
igenesis, we measured by qRT-PCR a panel of miRNAs in
MYC-induced transgenic models of tumorigenesis.
First, we developed a protocol optimized for collection,
storage and shipping of whole mouse blood, RNA extrac-
tion from a small volume of stored sample, and qRT-PCR
assays for mouse blood miRNA profiling. To enable blood
to be collected from mice at different time points and
stored so that total RNA extraction and miRNA quantita-
tion could be batch analyzed, mouse blood was mixed
with an RNA stabilizing reagent (RNAlater® Tissue Collec-
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tion:RNA Stabilization Solution, Ambion), transported,
and stored at -20 deg C. Total RNA extraction was subse-
quently performed using the Mouse RiboPure™ Blood kit
(Ambion).
Total RNA yields from cardiac puncture samples from 6
mice averaged 114 μg by NanoDrop measurement (Figure
1A). To determine the quality of total RNA extracted, Agi-
lent bioanalyzer scans were performed. RNA was found to
be intact as shown by the high RIN values observed in the
Agilent traces and the sharp 18S and 28S ribosomal RNA
(rRNA) peaks and lack of significant species between
those peaks (Figure 1B, C). The bioanalyzer traces also
showed a distinct peak that correlates with the recovery of
low molecular weight RNA including miRNA. The high
yields of RNA from mouse blood suggested that sufficient
RNA for analysis might be extracted from lower volume
tail vein bleeds that do not require sacrifice of the mouse.
Indeed, blood acquired via tail vein from eight mice
yielded an average of 15.8–33.7 μg RNA (Figure 1A). RNA
yields from even the lowest amounts of tail vein blood
were sufficient to run several hundred miRNA assays (as
described below). Our initial experiments thus estab-
lished the feasibility of carrying out blood miRNA profil-
ing on individual animals during time-course
experiments.
To determine which miRNAs could be readily detected in
mouse blood, a panel of 111 quantitative reverse tran-
scriptase PCR (qRT-PCR) SYBR miRNA assays was run on
initial samples of blood from normal mice (see Addi-
tional file 1). The qRT-PCR assays were normalized via
several methods, including 5S rRNA, U6 RNA, and global
mean. Results were validated through the detection of sev-
eral miRNA using TaqMan® qRT-PCR assays. High con-
cordance was observed in relative levels of blood miRNAs
as determined by the SYBR-based and TaqMan-based
assays, with a correlation value of 0.86 (Figure 1D). We
conclude that qRT-PCR is a highly sensitive approach for
identifying mouse blood miRNA profiles.
To characterize blood miRNA patterns in mice with can-
cer, we utilized our previously described conditional
transgenic mouse models of MYC-induced lymphoma,
hepatocellular carcinoma and osteosarcoma [31-37]. 30
miRNAs that were reproducibly detectable using our
methodology and known to be involved in the pathogen-
esis of cancer were selected for quantitation [5,14,16-
18,20,38,39]. Significant differences were found in 12/30
miRNA in blood of mice with lymphoma, and 8/30
miRNA in blood of mice with liver tumors compared with
normal controls (Figure 2). 25/30 miRNA for a mouse
with osteosarcoma were also significantly different from
normal controls, suggesting that further studies might be
warranted in other tumor models (see Additional file 2).
We conclude that changes in specific miRNAs can be
detected in the blood of transgenic mice with lymphoma,
hepatocellular carcinoma, and osteosarcoma. It is possi-
ble that we would have detected additional miRNA
changes in mice with liver cancer if we had measured a
broader panel of miRNAs. Alternatively, blood miRNA
changes may be more readily detected in hematopoietic
and mesenchymal tumors than in epithelial tumors.
Next, we attempted to identify specific changes in miRNA
profiles during lymphomagenesis. We performed qRT-
PCR from blood specimens collected from transgenic
mice before tumorigenesis (preneoplastic, n = 3), early
tumor formation (subclinical lymphoma, n = 2) and after
development of clinical lymphoma (overt lymphoma, n =
4). The results for a panel of 27 blood miRNA in all
groups were compared to values from mice without MYC
activation (normal control, n = 5) (Figure 3A). Unsuper-
vised hierarchical clustering analysis revealed that overt
lymphoma miRNA profiles grouped together. In mice
with overt lymphoma, we identified a decrease in 20 miR-
NAs, including let-7d and miR-16 (Figure 3A). Notably,
both of these miRNAs have been implicated in the patho-
genesis of cancer [5]. Importantly, we found that the
miRNA    profile in preneoplastic mice was markedly dif-
ferent from mice with overt lymphoma (Figure 3A).
Hence, our results suggest the possibility that the perform-
ance of miRNA measurements in mice might be useful to
monitor tumor development.
An important feature of our method is that its sensitivity
should allow for the analysis of serial blood specimens
from the same mouse. We obtained serial tail vein blood
samples from mice with MYC-induced lymphoma before
and after oncogene inactivation. The majority of miRNAs,
including members of the let-7 family, were detectable at
low levels and then increased upon tumor regression (Fig-
ure 3B) as early as 3 days after MYC inactivation even
though tumors did not fully regress until after 14 days.
Thus, changes in blood miRNA profiles can be deter-
mined from sequential peripheral blood samples drawn
from individual mice.
An important caveat of our studies is that we cannot deter-
mine the source of the miRNA changes. A priori, we could
be detecting miRNAs in rare circulating tumor cells or
from host cells that are influenced by tumor growth.
Regardless, the changes in miRNAs we see correlated with
tumor progression, and thus may be useful as biomarkers
of tumorigenesis.
Compared to microarray-based global miRNA profiling,
the real-time PCR assays used in our studies require sev-
eral magnitudes less input RNA and can be performed in
substantially less time. These features of our method makeMolecular Cancer 2008, 7:74 http://www.molecular-cancer.com/content/7/1/74
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High yields of intact RNA from stabilized mouse blood and use in qRT-PCR-based microRNA profiling Figure 1
High yields of intact RNA from stabilized mouse blood and use in qRT-PCR-based microRNA profiling. (A) 
Yield of RNA isolated using the Ambion® Mouse RiboPure™-Blood RNA Isolation kit. Blood samples were obtained by cardiac 
puncture or via tail vein bleed into a 2 mL tube preloaded with RNAlater® Solution. RNA was isolated, quantified, and exam-
ined on an Agilent® 2100 bioanalyzer (Agilent Technologies). Cardiac puncture samples were diluted 1:10 before running. Rep-
resentative bioanalyzer scans for (B) Quality of cardiac puncture blood RNA and (C) Quality of tail vein blood RNA are 
shown with major features marked. The lack of significant species between the peaks indicates that RNA is highly intact. (D) 
Comparison of SYBR®-based and TaqMan®-based miRNA quantitation. A panel of 26 miRNA were quantitated in blood from 
normal control mice using both SYBR qRT-PCR assays and TaqMan-based qRT-PCR assays. Correlation between results from 
the two methods was 0.86.
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it tractable for the detection of miRNA expression to iden-
tify early metastasis or minimal residual neoplastic cells.
Moreover, we found that specific blood miRNA profiles
mirrored specific types and states of cancer. Whether our
approach will also be useful for the analysis of human
patients remains to be determined. Finally, our method
appears to be applicable to the sequential analysis of
changes in miRNA expression in other models and in clin-
ical materials. Our approach may be useful to identify
biomarkers to detect early disease states and to predict
clinical response.
Materials and methods
Transgenic mice
The TRE-MYC transgenic lines generated for these experi-
ments were described previously [31-36,40-42]. The Eμ-
tTA transgenic line for lymphoid specific expression and
the Lt-tTA transgenic line for liver specific expression were
both kindly provided by H. Bujard [43]. Oncogene expres-
sion was suppressed in vivo by injecting mice intraperito-
neally with 20 μg of doxycycline in PBS and adding
doxycycline (200 μg/ml) to the drinking water.
Blood collection
Blood obtained by cardiac puncture from normal control
mice of Balb/c and C57BL/6 strains was purchased from
Jackson Labs (Bar Harbor MA). Blood from FVB/N and
(A) Comparison of relative blood miRNA profiles Figure 2
(A) Comparison of relative blood miRNA profiles. qRT-PCR results from 30 miRNA were compared in mice with 
MYC-induced lymphoma (black, n = 5), liver carcinoma (orange, n = 4) and healthy normal control mice without MYC overex-
pression (blue, n = 6). p-values < 0.05 for differences between liver carcinoma or lymphoma and normal individual miRNA are 
indicated with asterisks. MiRNA expression profiles were normalized with RNU6B. Mean ΔCt +/- standard error is graphed 
for each cohort.
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transgenic mice was collected at Stanford. To perform car-
diac puncture, mice were euthanized using carbon diox-
ide, then the ventricle was accessed with an 18 gauge
needle and 400–500 μl blood was aspirated into a 2 ml
syringe. Blood was immediately discharged into a 2 ml
microfuge tube preloaded with 1.3 ml RNAlater® Tissue
Collection:RNA Stabilization Solution (Ambion, Austin
TX), mixed by inversion, and stored at -20°C. To perform
blood collection by tail vein, mice were placed under a
heat lamp for 5 minutes, then a small peripheral tail inci-
sion was made. 2–10 drops of blood were collected
directly into a 2 ml microfuge tube preloaded with 1.3 ml
RNALater® Solution, mixed by inversion, and stored at -
20°C. An average drop of blood was determined to be 24
(A) Hierarchical clustering of blood miRNA profiles in mice at different stages of tumor initiation and regression Figure 3
(A) Hierarchical clustering of blood miRNA profiles in mice at different stages of tumor initiation and regres-
sion. Blood samples were collected from normal mice without MYC overexpression (normal control, n = 5), mice with MYC 
activation prior to tumorigenesis (preneoplastic, n = 3), mice with early tumor formation (subclinical lymphoma, n = 2), and 
mice with large, clinically detectable lymphomas (overt lymphoma, n = 4). MiRNAs were grouped using an unsupervised hierar-
chical clustering approach and the results (fold change) are displayed with TreeView 1.6. (B) Changes in miRNA profiles during 
tumor regression. Serial blood samples were obtained by tail vein bleed from three mice with MYC-induced lymphoma before 
MYC inactivation (Day 0), and after different timepoints of MYC inactivation. MiRNA qRT-PCR results (fold change) are dis-
played with TreeView 1.6.
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μl. Blood/RNAlater® Solution mixtures were shipped on
wet ice to a second site lab for RNA extraction and analy-
sis.
RNA extraction and analysis
The Ambion Mouse RiboPure™-Blood RNA Isolation kit
(AB cat #AM1951) was used for extraction of RNA. Briefly,
samples were centrifuged and the RNAlater®  Solution
removed prior to disruption of the blood pellet in a gua-
nidinium-based lysis solution, followed by organic extrac-
tion and purification of the total RNA fraction (including
small RNA) by solid phase extraction onto a silica matrix.
The Alternative Protocol described in the kit instruction
manual for samples less than 250 ul was used for extrac-
tion of RNA from the tail vein samples. RNA yields were
determined by UV absorbance using a Nanodrop instru-
ment (ND-1000 Spectrophotometer, NanoDrop Technol-
ogies) and intactness was examined on an Agilent® 2100
bioanalyzer (Agilent Technologies). The cardiac puncture
samples were diluted 1:10 before running.
MiRNA analysis was carried out using the mirVana qRT-
PCR primer sets (Ambion) and the TaqMan® MicroRNA
Assays (Applied Biosystems)(26). The mirVana qRT-PCR
assays used 10 ng of input total RNA that was analyzed
using target-specific primers for reverse transcription with
M-MLV reverse transcriptase, followed by PCR amplifica-
tion with a pair of miRNA target-specific primers and
detection with SYBR®  Green I nucleic acid gel stain
10,000× concentrate in DMSO (Invitrogen). Melting
curve analysis was carried out for each target to assess
amplification specificity; for some targets, non-specific
amplification was observed in the no-template negative
controls, which could not be discriminated by melt-curve
analysis. The TaqMan MicroRNA Assays used 10 ng of
input total RNA with miRNA-target-specific reverse tran-
scription primers and target-specific internal hybridiza-
tion probes ("TaqMan probes"), and were run in 96-well
or 384-well formats. qRT-PCR assays of similar design
(also purchased from Applied Biosystems) were carried
out for constitutively expressed small RNAs of similar size
to miRNAs (e.g. snoRNAs) and used for normalization of
input RNA amount (analogous to use of constitutive
mRNAs such as GAPDH for normalization of protein-cod-
ing genes).
The reverse transcription reactions were carried out for 65
min and used the AB TaqMan® microRNA Reverse Tran-
scription Kit (AB cat #4366597) which includes M-MLV
reverse transcriptase. Amplification reactions consisted of
a hold of 10 min at 95°C and 40 cycles (15 sec/95°C, 60
sec/60°C) on an Applied Biosystems 7900HT Real-Time
PCR System and required about 1.5 hours to complete.
The assays were carried out in duplicate or triplicate and
the geometric average Ct value was used to calculate rela-
tive expression for each datapoint. Unsupervised hierar-
chical clustering of samples was carried out with the
program Cluster 3.0. Each sample was used in multiple
experimental runs, and relative expression of different
miRNAs was determined using identical endogenous con-
trols in each experiment. Within each experiment, the
endogenous control that had the highest Ct was set as the
baseline, and the Ct between the baseline and the Ct of
the small RNA control in each sample was used as a nor-
malization factor that was added to the raw Ct for each
sample. Normalized Ct values larger than 35 were
reported as 35. After mean-centering the data for each
miRNA and using uncentered correlation similarity metric
and average linkage, the expression of miRNAs was hier-
archically clustered and displayed with the TreeView 1.6.
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